Currently, there are no FDA-approved therapies for FSGS. However, the therapeutic focal segmental glomerulosclerosis market in the seven major geographies mainly comprises off-label focal segmental glomerulosclerosis treatment options.
The off-label therapies majorly include nonimmune therapies in conjunction with immunotherapy. Nonimmune focal segmental glomerulosclerosis therapies include the control of blood pressure, lipids, and weight by prescribing angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARB) to the patient.
For severe cases, patients are suggested to undergo plasma exchange accompanied by immunotherapy, includi...
